{A figure is presented}Metabolic Tumor Burden Predicts for Disease Progression and Death in Lung Cancer

Percy Lee, Dilani K. Weerasuriya, Philip W. Lavori, Andrew Quon, Wendy Hara, Peter G. Maxim, Quynh Thu Le, Heather A. Wakelee, Jessica S. Donington, Edward E. Graves, Billy W. Loo

Research output: Contribution to journalArticle

153 Scopus citations


Purpose: In lung cancer, stage is an important prognostic factor for disease progression and survival. However, stage may be simply a surrogate for underlying tumor burden. Our purpose was to assess the prognostic value of tumor burden measured by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging. Patients and Methods: We identified 19 patients with lung cancer who had staging PET-CT scans before any therapy, and adequate follow-up (complete to time of progression for 18, and death for 15 of 19). Metabolically active tumor regions were segmented on pretreatment PET scans semi-automatically using custom software. We determined the relationship between times to progression (TTP) and death (OS) and two PET parameters: total metabolic tumor volume (MTV), and standardized uptake value (SUV). Results: The estimated median TTP and OS for the cohort were 9.3 months and 14.8 months. On multivariate Cox proportional hazards regression analysis, an increase in MTV of 25 ml (difference between the 75th and 25th percentiles) was associated with increased hazard of progression and of death (5.4-fold and 7.6-fold), statistically significant (p = 0.0014 and p = 0.001) after controlling for stage, treatment intent (definitive or palliative), age, Karnofsky performance status, and weight loss. We did not find a significant relationship between SUV and TTP or OS. Conclusions: In this study, high tumor burden assessed by PET MTV is an independent poor prognostic feature in lung cancer, promising for stratifying patients in randomized trials and ultimately for selecting risk-adapted therapies. These results will need to be validated in larger cohorts with longer follow-up, and evaluated prospectively.

Original languageEnglish (US)
Pages (from-to)328-333
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number2
StatePublished - Oct 1 2007


  • Automatic image analysis
  • Lung cancer
  • Metabolic tumor volume (MTV)
  • Positron emission tomography (PET)
  • Prognostic factors

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of '{A figure is presented}Metabolic Tumor Burden Predicts for Disease Progression and Death in Lung Cancer'. Together they form a unique fingerprint.

  • Cite this

    Lee, P., Weerasuriya, D. K., Lavori, P. W., Quon, A., Hara, W., Maxim, P. G., Le, Q. T., Wakelee, H. A., Donington, J. S., Graves, E. E., & Loo, B. W. (2007). {A figure is presented}Metabolic Tumor Burden Predicts for Disease Progression and Death in Lung Cancer. International Journal of Radiation Oncology Biology Physics, 69(2), 328-333. https://doi.org/10.1016/j.ijrobp.2007.04.036